checkAd

     273  0 Kommentare MindBio Therapeutics CEO Demonstrates how 1 Million Microdoses of LSD can Potentially be Used to Treat Depression at Scale - Seite 2

    MindBio Therapeutics, Tuesday, May 30, 2023, Press release picture

    MindBio Co-founder and Chief Executive Officer inspects GMP grade LSD to be used in MindBio's Phase 2 LSD-Microdosing clinical trials.

    We invite you to join us in support of creating a brighter future for mental health.

    Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates

    Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=tr ...

    Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/

    For further information, please contact:

    Justin Hanka, Chief Executive Officer
    61 433140886
    justin@mindbiotherapeutics.com

    About MindBio Therapeutics

    MindBio is a biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials microdosing Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2 clinical trial in development microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial in development microdosing LSD in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

    Cautionary Note Concerning Forward-Looking Statements:

    The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    MindBio Therapeutics CEO Demonstrates how 1 Million Microdoses of LSD can Potentially be Used to Treat Depression at Scale - Seite 2 1 Million Microdoses used by MindBio to create proprietary microdosing formulationMindBio scientists take delivery of GMP grade LSDLargest clinical trial repository of biometric, physiological and psychometric data for Microdosing in a big data play …

    Schreibe Deinen Kommentar

    Disclaimer